var data={"title":"Iopamidol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Iopamidol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6390?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=iopamidol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Iopamidol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26524992\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Isovue-200, Isovue-250, Isovue-300, and Isovue-370 are not for intrathecal use.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183910\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Isovue-200;</li>\n      <li>Isovue-250;</li>\n      <li>Isovue-300;</li>\n      <li>Isovue-370;</li>\n      <li>Isovue-M 200;</li>\n      <li>Isovue-M 300</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183913\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Contrast Agent;</li>\n      <li>\n        Iodinated Contrast Media;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Low Osmolality)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914544\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> General dosing guidelines are presented. Doses should be individualized and the lowest dose needed to obtain adequate visualization should be used. Patients should be well hydrated prior to and after administration. Refer to product information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Intravascular imaging:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Angiography:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cerebral arteriography: </i>Isovue-300: 8 to 12 mL by carotid puncture or transfemoral catheterization, with total multiple doses ranging to 90 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Coronary arteriography and ventriculography:</i> Isovue-370: 2 to 10 mL for selective coronary artery injection; 25 to 50 mL for ventriculography or nonselective opacification of multiple coronary arteries following injection at the aortic root. Total dose for combined procedures has not exceeded 200 mL. EKG monitoring is essential during procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Peripheral arteriography:</i> Isovue-300:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Femoral artery or subclavian artery: 5 to 40 mL up to a total of 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aorta for a distal runoff: 25 to 50 mL up to a total of 250 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Peripheral venography (phlebography):</i> Isovue-200: 25 to 150 mL per lower extremity. Combined total dose for multiple injections has not exceeded 350 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Selective visceral arteriography and aortography:</i> Isovue-370: Up to 50 mL may be required for injection into the larger vessels, such as the aorta or celiac artery; doses up to 10 mL may be required for injection into the renal arteries. Combined total dose for multiple injections has not exceeded 225 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Computed tomography: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CECT of the head:</i> IV: Imaging may be performed immediately after completion of administration.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-250:130 to 240 mL; maximum: 240 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-300: 100 to 200 mL; maximum: 200 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CECT of the body:</i> IV by rapid infusion or bolus injection:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-250: 130 to 240 mL; maximum: 240 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-300: 100 to 200 mL; maximum: 200 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Equivalent doses of Isovue-370 based on organically bound iodine content may also be used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urography, excretory:</b> Administer by rapid IV injection</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Isovue-250: 50 to 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Isovue-300: 50 mL</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">Isovue-370: 40 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Intrathecal imaging:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Computed tomographic cisternography:</b> Isovue-M 200: 4 to 6 mL via lumbar injection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myelography:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lumbar or thoracic myelogram:</i> Isovue-M 200: 10 to 15 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cervical myelogram (via lumbar injection):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-M 200: 10 to 15 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-M 300: 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cervical myelogram (via lateral cervical injection):</i> Isovue-M 200: 10 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Total columnar myelography:</i> Isovue-M 300: 10 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7976883\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> General dosing guidelines are presented. Doses should be individualized and the lowest dose needed to obtain adequate visualization should be used. Patients should be well hydrated prior to and after administration. Refer to product information for detailed dosing and administration information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Intravascular imaging: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Angiocardiography:</b> Isovue-370: <b>Note:</b> May be performed by injection into a large peripheral vein or direct catheterization of the heart:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;2 years: Single injection: 10 to 15 mL; cumulative injection: 40 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 4 years: Single injection: 15 to 30 mL; cumulative injection: 50 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 to 9 years: Single injection: 15 to 30 mL; cumulative injection: 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 to 18 years: Single injection: 20 to 50 mL; cumulative injection: 125 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Computed tomography:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CECT of the head and body:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-250: 1.2 to 3.6 mL/kg; maximum: 120 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Isovue-300: 1 to 3 mL/kg; maximum: 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urography, excretory:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Isovue-250: 1.2 to 3.6 mL/kg; should not be necessary to exceed a total dose of 120 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Isovue-300: 1 to 3 mL/kg; should not be necessary to exceed a total dose of 100 mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Intrathecal imaging:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myelography:</b> <i>Lumbar or thoracic myelogram:</i> Isovue-M 200:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to 7 years: 7 to 9 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">8 to 12 years: 8 to 11 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to 18 years: 10 to 12 mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914545\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962264\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in severe impairment, anuria, and in the setting of combined renal and hepatic disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962265\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use caution in patients with combined hepatic and renal disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183902\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isovue-M 200: 41% (10 mL, 20 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isovue-M 300: 61% (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isovue-200: 41% (50 mL, 200 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isovue-250: 51% (50 mL, 100 mL, 150 mL, 200 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isovue-300: 61% (30 mL, 50 mL, 75 mL, 100 mL, 125 mL [DSC], 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isovue-370: 76% (50 mL [DSC], 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183898\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914546\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Precautions should be taken to ensure products intended for IV administration are not administered intrathecally.</b> Patients should be well hydrated prior to and following procedure. Premedication with antihistamines or corticosteroids may be considered in some patients to minimize the potential for allergic reactions. Solutions should be at body temperature prior to administration. In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guidewire manipulation. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Intrathecal:</b> Administer slowly over 1 to 2 minutes to avoid excessive mixing with CSF through a lumbar needle under fluoroscopic control.  If repeat examination is needed, an interval of at least 48 hours should be allowed; whenever possible 5 to 7 days is recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>not</b> flush the line); remove needle/cannula; initiate hyaluronidase antidote; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hyaluronidase:</i> Intradermal or SubQ: Inject a total of 1 mL (15 units/mL) as five separate 0.2 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (MacCara, 1983; Zenk, 1981) or injection of a total of 5 mL (150 units/mL) as five separate 1 mL injections around the extravasation site has been also used successfully (Rowlett, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183903\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angiography:</b> <i>Isovue</i>: Diagnostic agent for angiography throughout the cardiovascular system, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography (phlebography).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Computed tomography: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Isovue:</i> Diagnostic agent for adult and pediatric contrast enhancement of computed tomographic (CECT) head and body imaging.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Isovue-M: </i> Diagnostic agent for CECT cisternography and ventriculography in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelography:</b> <i>Isovue-M:</i> Diagnostic agent for myelography (lumbar, thoracic, cervical, total columnar) in adults; diagnostic agent for myelography (lumbar, thoracic) in children &gt;2 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urography:</b> <i>Isovue:</i> Diagnostic agent for adult and pediatric excretory urography.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174549\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914490\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris (3%), flushing (2%), bradycardia (1%), hives (1%), hypotension (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache (&le;16%), pain (3%), burning sensation (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash (2% to 3%), hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea (1% to 7%), vomiting (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain (2%), leg pain (1%), neck pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&le;1%, postmarketing, and/or case reports: Abdominal cramps, abnormal aspartate transaminase, abnormal blood platelet aggregation, abnormal serum calcium, abnormal uric acid levels, amnesia (temporary), anaphylactoid reaction, anorexia, apnea, arterial spasm, asthma, ataxia, atrioventricular block, back spasm, bacterial meningitis, bigeminy, cardiac arrhythmia, change in creatinine, change in RBC count, change in WBC count, chest pain, chest tightness, chills, circulatory shock, cold extremities, coma, confusion, conjunctivitis, constriction of the pharynx, cortical blindness (temporary), cough, decreased partial thromboplastin time, decreased prothrombin time, decreased serum fibrinogen, depression of ST segment on ECG, diaphoresis, diarrhea, dizziness, dysgeusia, dyspnea, EEG pattern changes (usually slow wave activity), erythrocyte agglutination, exacerbation of decreased peripheral perfusion, extrasystoles, eye pruritus, facial edema, facial grimace, fatigue, fever, genitourinary pain, hallucination, hearing loss (transitory), heartburn, hematuria, hypersensitivity reaction, hypertension, increased left ventricular end-diastolic pressure, involuntary muscle movements, irritability, lacrimation, laryngeal edema, leg cramps, localized irritation (cervicobrachial, meningeal, lumbosacral radicular), malaise, muscle spasm, musculoskeletal pain, myasthenia, myocardial infarction, nasal congestion, neurological signs and symptoms, numbness, pain at injection site (usually due to extravasation and/or erythematous swelling), pallor, paralysis, paresthesia, periorbital edema, peripheral neuropathy, pruritus, pulmonary edema, renal disease (contrast-associated), renal infarction, renal tubular necrosis (with oliguria and anuria), retching (severe), rhinitis, sciatica, seizure (focal and motor), signs and symptoms of aseptic meningitis, skin rash, sneezing, stress, syncope, systolic hypotension, tachycardia, thrombophlebitis, tingling of the arms, tinnitus, transient ischemic attacks, tremor, trigeminal neuralgia, urinary retention, urticaria, vasodepressor syncope, vasodilatation, ventricular fibrillation, visual disturbance, watery eyes, weakness, worsening of cyanosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183905\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous: There are no contraindications listed in the manufacturers labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: Concurrent intrathecal corticosteroid administration; immediate repeat myelography in the event of technical failure (potential for overdose); significant local or systemic infection where bacteremia is likely (myelography only).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to iopamidol or any component of the formulation; significant renal and/or hepatic impairment; direct intracisternal administration or gravitational displacement of a concentrated bolus of iopamidol into the intracranial subarachnoid spaces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914489\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast-induced hypersensitivity reactions: Adverse reactions (including delayed reactions) to iodine-containing contrast media have occurred. Most cases are minor; however, serious and life-threatening reactions may occur without warning and often resemble allergic-type reactions. Severe cutaneous hypersensitivity reactions (including Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], acute generalized exanthematous pustulosis [AGEP], drug reaction with eosinophilia and systemic symptoms [DRESS]) have occurred 1 hour to 1 week after administration; reaction severity may increase and time to onset may decrease with repeat administration. Patients with a history of bronchial asthma, allergy (including food allergy), family history of allergy, or prior allergy or hypersensitivity to contrast agents are at a higher risk for allergic reaction. Obtain allergy and hypersensitivity history prior to administration. Pretesting for allergic reaction may not reliably predict potential for reaction. Premedication with antihistamines and corticosteroids should be considered in patients at risk for allergic reaction (strong allergy history, prior contrast media reaction, or positive pretest) to reduce the incidence and severity of reactions. Monitor closely for 30 to 60 minutes after administration of the contrast media. A higher incidence of adverse reactions was reported in patients also receiving general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contrast-associated acute kidney injury: Acute kidney injury, including renal failure, may occur following administration of iodinated contrast media. Risk factors include patients with preexisting renal disease, advanced age, advanced vascular disease, heart failure, dehydration, diabetes, concomitant use of nephrotoxic agents or diuretics, multiple myeloma, or large doses or multiple doses of iodinated contrast media. Adequately hydrate patients prior to and following administration to minimize the risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Vesicant; ensure proper needle/catheter/line placement prior to and during administration. Avoid infiltration. Extravasation may result in tissue necrosis and/or inflammation, particularly in patients with severe arterial or venous disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Avoid in patients with history of epilepsy unless medically justified; focal and generalized motor seizures have been reported after intrathecal use; antiepileptic therapy should be continued. Premedication with barbiturates or phenytoin should be considered in patients with a history of seizure activity not currently on anticonvulsant therapy. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAO inhibitors, tricyclic antidepressants, CNS stimulants), should be discontinued 24 to 72 hours prior to intrathecal use and not resumed for 24 hours postprocedure (ACR, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Serious, rarely fatal, thromboembolic events causing MI and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation (more than nonionic contrast media). Use meticulous intravascular administration techniques during angiographic procedures. Clotting has been reported when in vitro blood remains in contact with syringes containing nonionic contrast media; use of plastic syringes in place of glass syringes has been reported to decrease, but not eliminate, the likelihood of in vitro clotting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, especially when combined with renal impairment; severe, life-threatening, and fatal cardiovascular reactions have occurred. Observe patients with heart failure for several hours following the procedure to detect delayed hemodynamic disturbances, which may be associated with a transitory increase in the circulating osmotic load. Perform selective coronary angiography only if the anticipated benefit outweighs potential risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes; these patients may have altered renal blood flow, increasing the risk of nephrotoxicity. Preparatory dehydration may contribute to acute renal failure in patients with diabetes; avoid fluid restriction and maintain normal hydration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with combined renal and hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Homocystinuria: Avoid angiography in patients with homocystinuria; may be at risk for thrombosis and embolism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: Use with caution in patients with multiple myeloma or other paraproteinemia, particularly in those with resistant anuria; use of intravascular contrast agents may lead to renal impairment, especially with concurrent dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; administration of contrast media may result in disease exacerbation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with extreme caution in patients with pheochromocytoma (known or suspected). Minimize the amount of contrast agent used (for intravascular administration) and monitor blood pressure closely throughout procedure. Therapy for treatment of hypertensive crisis should be readily available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment, combined renal and hepatic impairment, or anuria, especially if large doses or repeat doses are needed. Preparatory dehydration may contribute to acute renal failure in patients with preexisting renal impairment. Acute renal failure has been reported in patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disease: Use with caution in sickle cell disease; may promote sickling in patients homozygous for sickle cell disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Thyroid storm has been reported following intravascular use of iodinated radiopaque agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule. Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been reported (uncommon) in adult and pediatric patients (including infants); some patients were treated for hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients. Preparatory dehydration may contribute to acute renal failure in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatrics: Pediatric patients at higher risk of experiencing adverse events during contrast medium administration may include those having asthma, sensitivity to medication or allergens, cyanotic heart disease, heart failure, serum creatinine &gt;1.5 mg/dL, or those &lt;12 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&bull; Appropriate use:<b> [US Boxed Warning]: Isovue-200, Isovue-250, Isovue-300, and Isovue-370 are not for intrathecal use.</b> Serious adverse reactions (eg, acute renal failure, arachnoiditis, cardiac arrest, cerebral hemorrhage, coma, seizures, brain edema, hyperthermia, paralysis, rhabdomyolysis, death) have been reported due to inadvertent intrathecal administration of iodinated contrast agents not indicated for intrathecal use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&bull; Appropriate use: <i>Intrathecal administration (Isovue-M 200 and Isovue-M 300 only): </i> Direct intracisternal or ventricular administration for standard radiography (without computerized tomographic enhancement) is not recommended. Avoid inadvertent intracranial administration of large dose or concentrated bolus of contrast medium; avoid rapid dispersion of medium, which could lead to inadvertent rise in intracranial levels (as may occur with active patient movement). If such intracranial entry of the medium occurs, prophylactic anticonvulsant treatment with diazepam or barbiturates orally for 24 to 48 hours should be considered. Use intrathecal administration with caution in patients with multiple sclerosis, increased intracranial pressure or suspicion of intracranial tumor, abscess, hematoma, chronic alcoholism, and the elderly. If frankly bloody cerebrospinal fluid is observed, the anticipated benefit versus the potential risks should be considered prior to myelography.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&bull; Appropriate use: <i>Intravascular administration:</i> In angiographic procedures, during catheter manipulations and contrast medium injection, a possibility of dislodging plaques or damaging (or perforating) vessel walls exists. Ensure proper catheter placement with test injections. In contrast-enhanced computerized tomography (CECT), contrast may obscure some lesions previously seen on unenhanced CT scans.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&bull; Appropriate use: Coronary arteriography: Use with caution in patients with chronic pulmonary emphysema.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&bull; Appropriate use: Venography: Use with caution in patients with suspected thrombosis, phlebitis, severe ischemic disease, local infection, or a totally obstructed venous system. Fluoroscopy is recommended, especially in patients with severe arterial or venous disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&bull; Trained personnel: Clinicians using radiopaque contrast agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use during and for 30 to 60 minutes after administration (delayed reactions have occurred).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299531\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221095\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8932&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents With Seizure Threshold Lowering Potential: May enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: May enhance the potential for allergic or hypersensitivity reactions to Iodinated Contrast Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Management advice varies. Refer to the full drug interaction monograph content for details.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183900\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183907\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Iopamidol crosses the placenta and can be detected in the newborn gut at birth (Fitzpatrick 2011; Huang 2014). Thyroid dysfunction in the neonate has not been reported (ACR 2015; Atwell 2011). In general, use of iodinated contrast media should be avoided unless absolutely required to obtain diagnostic information that will influence the care of the mother or fetus during pregnancy (ACOG 2016; ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914488\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Because of the low expected excretion of iodinated contrast agents into breast milk and the low absorption from an infant's GI tract, breast-feeding may be continued without interruption after use (ACOG 2016; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015). The manufacturer recommends that caution be exercised when administering iopamidol to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9836149\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25314416\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hydration; signs/symptoms of hypersensitivity during and for at least 30 to 60 minutes following procedure; renal function; extravasation during IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Coronary arteriography, ventriculography:</i> EKG monitoring is essential during procedure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914497\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914499\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: ~2 hours; prolonged in renal impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 90% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323205\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isovue-200 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">41% (50 mL): $50.57</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isovue-250 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">51% (100 mL): $92.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isovue-300 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">61% (200 mL): $113.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isovue-370 Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">76% (125 mL): $138.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isovue-M 200 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">41% (10 mL): $77.55</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isovue-M 300 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">61% (15 mL): $103.04</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F183908\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amidol 370 (BD);</li>\n      <li>Gastromiro (IE);</li>\n      <li>Iopamed (EC, PE);</li>\n      <li>Iopamigita (HR, LV, SI, SK);</li>\n      <li>Iopamiro (AE, BG, CH, EE, EG, ES, GR, HK, HN, HR, HU, IL, IT, JO, KW, LT, NL, PH, PL, PT, QA, RO, SA, SE, SG, TR, TW);</li>\n      <li>Iopamiron (CO, EC, FR, PY, UY, VE, VN);</li>\n      <li>Isovue (AU, NZ);</li>\n      <li>Jopamiro (AT);</li>\n      <li>Lopamiro 300 (BD);</li>\n      <li>Lopidam 370 (BD);</li>\n      <li>Niopam (IE);</li>\n      <li>Pamidol (LK);</li>\n      <li>Pamiray (DO, KR);</li>\n      <li>Pamitra (PE);</li>\n      <li>Radisense (PK);</li>\n      <li>Scanlux (AE, JO, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 656: guidelines for diagnostic imaging during pregnancy and lactation. <i>Obstet Gynecol</i>. 2016;127(2):e75-e80. doi:10.1097/AOG.0000000000001316.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/26942391/pubmed\" target=\"_blank\" id=\"26942391\">26942391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2013. Available at http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013_Contrast_Media.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, &ldquo;Practice Guideline for the Performance of Myelography and Cisternography,&rdquo; Available at http://gm.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/head-neck/myelography.aspx</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology, &ldquo;ACR Manual on Contrast Media, Version 10&rdquo;, 2015. Available at: http://www.acr.org/quality-safety/resources/contrast-manual.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atwell TD, Lteif AN, Brown DL, McCann M, Townsend JE, Leroy AJ. Neonatal thyroid function after administration of IV iodinated contrast agent to 21 pregnant patients. <i>AJR Am J Roentgenol</i>. 2008;191(1):268-271. doi: 10.2214/AJR.07.3336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/18562757/pubmed\" target=\"_blank\" id=\"18562757\">18562757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. MedWatch. Iodine-containing contrast agents for medical imaging. Food and Drug Administration website. Available at <a href=\"http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm\" target=\"_blank\">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm472995.htm</a>. Updated November 17, 2015. Accessed November 18, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fitzpatrick J, Speakman J, Kapfer SA, Holston AM. Transplacental passage of the non-ionic contrast agent iopamidol in twins. <i>Pediatr Radiol</i>. 2011;41(4):534-536. doi: 10.1007/s00247-010-1888-z.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/21072507/pubmed\" target=\"_blank\" id=\"21072507\">21072507</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang TK, Reese J, Weitkamp JH, Stancombe BB. Congenital radiocontrast agent in the neonatal gut. <i>J Pediatr</i>. 2014;164(5):1236-1236.e1. doi: 10.1016/j.jpeds.2014.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/24534573/pubmed\" target=\"_blank\" id=\"24534573\">24534573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isovue (iopamidol) [product monograph]. Montreal, Quebec, Canada: Bracco Imaging Canada; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isovue-200, Isovue-250, Isovue-300, Isovue-370 (iopamidol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isovue-300, Isovue-370 Bulk Package (iopamidol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isovue-M 200, Isovue-M 300 (iopamidol) [prescribing information]. Monroe Township, NJ: Bracco Diagnostics; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isovue-250, Isovue-300, Isovue-370 (iopamidol) pharmacy bulk package [prescribing information]. Monroe Township, NJ: Bracco Diagnostics; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2012, 126(7):875-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/22800849/pubmed\" target=\"_blank\" id=\"22800849\">22800849</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo; <i>Catheter Cardiovasc Interv</i>, 2009, 74(4):728-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/19830793/pubmed\" target=\"_blank\" id=\"19830793\">19830793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/17692741/pubmed\" target=\"_blank\" id=\"17692741\">17692741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowlett J. Extravasation of contrast media managed with recombinant human hyaluronidase. <i>Am J Emerg Med</i>. 2012;30(9):2102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/iopamidol-drug-information/abstract-text/22633726/pubmed\" target=\"_blank\" id=\"22633726\">22633726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zenk KE. Management of Intravenous Extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8932 Version 104.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F26524992\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F183910\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F183913\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7914544\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7976883\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7914545\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15962264\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15962265\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F183902\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F183898\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7914546\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F183903\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174549\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7914490\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F183905\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7914489\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299531\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221095\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F183900\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F183907\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7914488\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9836149\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F25314416\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7914497\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7914499\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323205\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F183908\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8932|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=iopamidol-patient-drug-information\" class=\"drug drug_patient\">Iopamidol: Patient drug information</a></li></ul></div></div>","javascript":null}